Regimen Reference Order - MYEL - lenalidomide + dexamethasone

ARIA: MYEL - [lenalidomide + dexamethasone (1st Line)]

Planned Course: Every 28 days until disease progression or unacceptable toxicity Indication for Use: Multiple Myeloma Transplant Ineligible – First Line Treatment

Proceed with treatment if:

ANC equal to or greater than 1 x $10^9/L$ AND Platelets equal to or greater than 30 x $10^9/L$

Contact prescribing hematologist if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
Drug	Dose	CCMB Administration Guideline		
Not Applicable				

Drug	Dose	CCMB Administration Guideline
examethasone	40 mg	Orally once daily with food on Days 1, 8, 15 and 22 (Self-administered at home)
nalidomide	25 mg	Orally once daily with or without food on Days 1 to 21 Swallow whole (Self-administered at home)

Classification: Cytotoxic, Hazardous

REQUIRED MONITORING

Day 1

- CBC, creatinine, calcium, albumin, random glucose, liver enzymes and TSH as per Physician Orders
- Serum Protein Electrophoresis (SPEP)/Free Light Chain Ratio (FLCH) (response assessment)

Day 15 (required for the first 4 cycles)

• CBC as per Physician Orders

Per RevAid Program or Reddy2Assist Program-See Additional Information

 $\bullet \ \ Patients \ of child bearing \ potential \ require \ \beta HCG \ according \ to \ RevAid \ Program/Reddy 2 Assist \ Program \ requirements$

	Recommended Support Medications		
ı	Drug	Dose	CCMB Administration Guideline
	acetylsalicylic acid (ASA) enteric coated	81 mg delayed release	Orally once daily



INSTRUCTIONS FOR PATIENT

- Remind patient to take ASA (antiplatelet) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on lenalidomide

ADDITIONAL INFORMATION

- Patients should take therapy to prevent blood clots while on lenalidomide. The majority of patients will be prescribed
 acetylsalicylic acid (ASA) enteric coated 81 mg once daily. Patients at high risk may be prescribed other anticoagulants
 instead of acetylsalicylic acid
- lenalidomide is teratogenic
- Patients of childbearing potential will require monthly pregnancy tests (βHCG) that must be done within 7 days of the next prescription fill
- Effective November 25th, 2021, all <u>new patients</u> starting on lenalidomide will be enrolled in Reddy2Assist Program and lenalidomide will be dispensed by CCMB Pharmacy. lenalidomide can only be given to patients who are registered and meet all conditions of Reddy2Assist Program
- Existing patients on lenalidomide (started prior to November 25th, 2021) are currently enrolled in RevAid Program and will continue to have their lenalidomide prescriptions dispensed by the RevAid Registered Pharmacy

